Comparison of acute and delayed antiemetic effect of adding Aprepitant to Odansitron and Dexamethasone regimen in patients with Hodgkin lymphoma receiving highly emetogenic chemotherapy
Cancer is a class of disease in which group of cells show out of control growth, invasions and sometimes metastasis to different parts of the body. Few side effects of cancer treatment are more feared by the patient than nausea and vomiting. Although nausea and emesis (vomiting and retching) can result from surgery or radiation therapy, chemotherapy-induced nausea and vomiting (CINV) are potentially the most severe and most distressing. A randomized, single-blind controlled clinical trial conducted in Hiwa Center for Cancer in Sulaimani city for the period from January to December 2015. A total of 70 Hodgkin lymphoma patients presented to Hiwa Center for Cancer and treated with ABVD chemotherapy regimen were selected. The patient's received either the treatment (Aprepitant, Odansitron and Dexamethasone) or the standard regimen (Odansitron, Dexamethasone) in a 1:1 ratio, computer-generated, random allocation schedule. A total of sixty-three Hodgkin lymphoma patients were included in the present study with a mean age was 47.8±14.4 years; 34.9 % of them were ageing 60 years and more. Nausea and vomiting score was significantly higher in the treatment group from 2nd day to 4th days; the number of rescue therapy was significantly higher in the standard therapy group. In conclusion, the use of Aprepitant, Odansitron and Dexamethasone regimen showed superior and valuable results in the prevention of cancer induced nausea and vomiting by patients on chemotherapy.
PDF Downloaded: 89
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.